In March 2025, Bavarian Nordic A/S (OMX: BAVA) announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS® (Smallpox and Mpox Vaccine, Live, Non-replicating) for the prevention of smallpox and mpox in adults 18 years and older. This approval enhances flexibility for stockpiling in response to smallpox or mpox outbreaks.
